Results of the SELECT trial, which originally studied over 17,000 adults with heart disease and a body mass index (BMI) 27kg/m, comparing semaglutide to placebo, demonstrated that that those taking the drug for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
Metab Brain Dis 30(3):615632 Lawrence TP, Steel A, Ezra M, Speirs M, Pretorius PM, Douaud G, Sotiropoulos S, Cadoux-Hudson T, Emir UE, Voets NL (2019) MRS and DTI evidence of progressive posterior cingulate cortex and corpus callosum injury in the hyper-acute phase after traumatic brain injury
Pavlotsky, F
Consider scheduling a consultation with a wellness professional at Peach IV who is experienced in NAD+ therapies
Bile salts are the primary driver of bile flowing from the liver into the gallbladder and out into the small intestine
Liraglutide and semaglutide were the most frequently investigated GLP-1RAs
